Skip to main content
SpringerLink
Log in

Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis

Bewertung des Oxidant- und Antioxidant-Status sowie der Beziehung zur Prolidase bei systemischer Sklerose

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Purpose

Systemic sclerosis (SSc) is a disease characterized by fibrosis of the skin and organs; it is associated with diffuse fibroproliferative microangiopathy and autoimmune background. The studies have shown that the production of excessive free radicals and increased collagen synthesis by the fibroblasts play an important role in the pathophysiology of SSc. Prolidase is an important marker in collagen turnover. We aimed to compare total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), and prolidase levels of SSc patients and healthy controls. We also investigated the relationship between prolidase and oxidative stress.

Methods

A total of 38 SSc patients and 33 healthy volunteers were included in the study. Serum TAS, TOS, and prolidase activity were evaluated in the groups.

Results

It was found that the TOS and OSI levels of patients were higher than those in the control group (P = 0.012 and 0.015, respectively), whereas TAS was not significantly different between groups (P = 0.451). Prolidase activity was lower in patients than in controls (P = 0.008). There was a weak correlation between prolidase and OSI in patients. It was found that TAS was lower by marginal significance in the patients with lung and gastrointestinal tract (GT) involvement than the patients without those (P = 0.067 and 0.059, respectively).

Conclusions

Our data suggest that oxidative stress is increased in SSc. TAS is decreased in patients with lung and GT involvement. These results support that antioxidant treatment may be useful in SSc, especially in patients with lung and GT involvement. Antioxidant treatment may prevent organ involvement in SSc. TAS may be a marker that predicts the risk of involvement of a specific organ. In addition, prolidase may be a marker of SSc.

Zusammenfassung

Ziel der Studie

Die systemische Sklerose (SSc) ist eine Erkrankung, die durch Fibrose der Haut und der Organe gekennzeichnet ist; sie ist vergesellschaftet mit einer diffusen fibroproliferativen Mikroangiopathie und einem autoimmunen Hintergrund. Es konnte in verschiedenen Studien gezeigt werden, dass die überschießende Produktion von freien Radikalen und die gesteigerte Kollagensynthese durch Fibroblasten eine wichtige Rolle in der Pathophysiologie der SSc spielen. Prolidase ist ein wichtiger Marker des Turnovers von Kollagen. Ziel unserer Studie war es, den gesamten oxidativen Status (TOS), den gesamten antioxidativen Status (TAS), den oxidativen Stress Index (OSI) und die Serum-Konzentrationen der Prolidase bei Patienten mit SSc und bei gesunden Kontrollen zu erheben. Außerdem untersuchten wir, ob ein Zusammenhang zwischen Prolidase und oxidativem Stress besteht.

Methodik

38 Patienten mit SSc und 33 gesunde Freiwillige wurden in die Studie aufgenommen. Serum TAS, TOS und Prolidase-Aktivität wurden in beiden Gruppen erhoben.

Ergebnisse

Die TOS und OSI waren bei den Patienten höher als bei der Kontrolle (P = 0,012 beziehungsweise 0,015). Die TAS unterschied sich allerdings nicht signifikant zwischen beiden Gruppen (P = 0,451). Die Aktivität der Prolidase war bei den Patienten niedriger als bei den Gesunden (P = 0,008). Bei den Patienten bestand eine schwache Korrelation zwischen Prolidase und dem OSI. Bei den Patienten mit Beteiligung der Lunge und des Gastrointestinaltraktes (GI-Trakt) waren die TAS grenzwertig signifikant niedriger (P = 0,067 beziehungsweise 0,059) als bei den Patienten ohne Befall dieser Organe.

Schlußfolgerungen

Unsere Ergebnisse lassen vermuten, dass der oxidative Stress bei SSc erhöht ist. TAS ist bei Beteiligung der Lungen und des GI-traktes erniedrigt. Eine antioxidative Behandlung könnte daher bei SSc – vor allem wenn Lungen und GI-Trakt befallen sind, von Nutzen sein. Diese Behandlung könnte der Organbeteiligung vorbeugen. TAS könnte ein Marker sein, der das Risiko des Befalls eines bestimmten Organs vorhersagt. Außerdem könnte die Prolidase ein Marker der SSc sein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587–95.

    Article  CAS  PubMed  Google Scholar 

  2. Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrel’s hypothesis revisited. Semin Immunopathol. 2008;30:329–37.

    Article  CAS  PubMed  Google Scholar 

  3. Murrell GAC, Francis MJO, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J. 1990;265:659–65.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Physician. 2008;78:961–8.

    PubMed  Google Scholar 

  5. Eckes B, Mauch C, Huppe G, Krieg T. Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma. Biochem J. 1996;315:549–54.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Myara I, Charpentier C, Lemonnier A. Minireview: prolidase and prolidase deficiency. Life Sci. 1984;34:1985–98.

    Article  CAS  PubMed  Google Scholar 

  7. Surazynski A, Miltyk W, Palka J, Phang JM. Prolidase-dependent regulation of collagen biosynthesis. Amino Acids. 2008;35:731–8.

    Article  CAS  PubMed  Google Scholar 

  8. Masi AT, Rodnan GP, Medsger TA, Jr, Altman RD, D’Angelo WA, Fries JF, et al. Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum. 1980;23:581–90.

    Article  Google Scholar 

  9. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–5.

    CAS  PubMed  Google Scholar 

  10. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S, et al. European multicenter study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Medsger TA, Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26:2159–67.

    PubMed  Google Scholar 

  12. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by praline colorimetric determination: application to iminodipeptiduria. Clin Chim Acta. 1982;125:193–205.

    Article  CAS  PubMed  Google Scholar 

  13. Chinard FP. Photometric estimation of proline and ornithine. J Biol Chem. 1952;199:91–5.

    CAS  PubMed  Google Scholar 

  14. Erel OA. Novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–9.

    Article  CAS  PubMed  Google Scholar 

  15. Koc S, Aksoy N, Bilinc H, Duygu F, Uysal IO, Ekinci A, et al. Paraoxonase and arylesterase activity and total oxidative/antioxidative status in patients with chronic adenotonsillitis. Int J Pediatr Otorhinolaryngol. 2011;75:1364–7.

    Article  PubMed  Google Scholar 

  16. Erel OA. New automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–11.

    Article  CAS  PubMed  Google Scholar 

  17. Kosecik M, Erel O, Sevinc E, Selek S. Increased oxidative stress in children exposed to passive smoking. Int J Cardiol. 2005;100:61–4.

    Article  PubMed  Google Scholar 

  18. Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol. 1998;25(2):314–7.

    CAS  PubMed  Google Scholar 

  19. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44(11):2653–64.

    Article  CAS  PubMed  Google Scholar 

  20. Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 1996;39(7):1146–50.

    Article  CAS  PubMed  Google Scholar 

  21. Herrick AL, Matucci CM. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol. 2001;19(1):4–8. Review.

    CAS  PubMed  Google Scholar 

  22. Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. 2000;155(1–3):1–15.

    CAS  PubMed  Google Scholar 

  23. Tikly M, Channa K, Theodorou P, Gulumian M. Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol. 2006;25(3):320–4.

    Article  PubMed  Google Scholar 

  24. Kalin R, Righi A, Del Rosso A, Bagchi D, Generini S, Cerinic MM, et al. Activin, a grape seed-derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. Free Radic Res. 2002;36(8):819–25.

    Article  PubMed  Google Scholar 

  25. Ogawa F, Shimizu K, Muroi E, Hara T, Sato S. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol. 2011;30:921–5.

    Article  PubMed  Google Scholar 

  26. Rosato E, Rossi C, Molinaro I, Giovannetti A, Pisarri S, Salsano F. Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. Int J Immunopathol Pharmacol. 2011;24(3):727–33.

    CAS  PubMed  Google Scholar 

  27. Ogawa F, Shimizu K, Hara T, Muroi E, Komura K, Takenaka M, et al. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Arch Dermatol Res. 2010;302:27–35.

    Article  CAS  PubMed  Google Scholar 

  28. Musellim B, Ikitimur H, Uzun H, Ongen G. The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int. 2006;27(2):163–7.

    Article  CAS  PubMed  Google Scholar 

  29. Gabriele S, Alberto P, Sergio G, Fernanda F, Marco MC. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. 2000;155:1–15.

    Article  CAS  PubMed  Google Scholar 

  30. Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford). 1999;38(4):309–15.

    Article  CAS  Google Scholar 

  31. Ocakci A, Coskun O, Tumkaya L, Kanter M, Gurel A, Hosnuterd M, et al. Beneficial effects of ebselen on corrosive esophageal burns of rats. Int J Pediatr Otorhinolaryngol. 2006;70(1):45–52.

    Article  PubMed  Google Scholar 

  32. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int. 2007;27:339–44.

    Article  CAS  PubMed  Google Scholar 

  33. Yildiz A, Demirbag R, Yilmaz R, Gur M, Altiparmak IH, Akyol S, et al. The association of serum prolidase activity with the presence and severity of coronary artery disease. Coron Artery Dis. 2008;19(5):319–25.

    Article  PubMed  Google Scholar 

  34. Shrinath M, Walter JH, Haeney M, Couriel J, Lewis M, Herrick A. Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child. 1997;76(5):441–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Langberg H, Skovgaard D, Asp S, Kjaer M. Time pattern of exercise-induced changes in type I collagen turnover after prolonged endurance exercise in humans. Calcif Tissue Int. 2000;67(1):41–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Social Medicine, Department of Internal Medicine, Gaziantep University Faculty of Medicine, 27100, Sahinbey, Gaziantep, Turkey

    Esen Savas MD

  2. Department of Biochemistry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey

    Nur Aksoy & Mustafa Örkmez

  3. Division of Rheumatology, Department of Internal Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Turkey

    Yavuz Pehlivan & Ahmet Mesut Onat

  4. Department of Internal Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Turkey

    Zeynel Abidin Sayiner

  5. Division of Geriatric Medicine, Department of Internal Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Turkey

    Zeynel Abidin Öztürk

  6. Division of Endocrinology, Department of Internal Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Turkey

    Suzan Tabur

Authors
  1. Esen Savas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nur Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yavuz Pehlivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zeynel Abidin Sayiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zeynel Abidin Öztürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suzan Tabur
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mustafa Örkmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ahmet Mesut Onat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esen Savas MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Savas, E., Aksoy, N., Pehlivan, Y. et al. Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien Klin Wochenschr 126, 341–346 (2014). https://doi.org/10.1007/s00508-014-0534-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-014-0534-4

Keywords

Schlüsselwörter

Search

Navigation